Every drug discovery program has its own challenges. Scientists at Reaction Biology have 20 years of experience in problem-solving and decision making. Via blogs, we like to share some of our experiences and insight into our assays with the drug discovery community to support your journey to a preclinical drug candidate.
Modelling bladder cancer (BC) for preclinical drug development is notoriously challenging. Due to the route of administration of BC treatments, orthotopic modelling represent the go-to-option for physiological relevance. Here we review current resources for in vivo BC research and describe the characterization of the MB49_luc bioluminescent model.
Running cell-based assays in multiple ways provides an opportunity to view a kinase inhibitor in action from different angles. At Reaction Biology, we offer three assay formats for cell-based kinase screening. In this blog, we compare the assay formats to help you choose the assay that is right for your research project.
While biochemical assays will likely remain a critical entry point for novel molecules into the kinase inhibitor drug discovery pipeline, the field has collectively achieved a state of maturation that increasingly demands priority for cell-based assays right out of the gate.
The ability of several small molecule kinase inhibitors to modulate immune responses, as well as potentially block various stages in SARS-CoV-2 life cycle suggests they may have an important role in the emerging therapeutic arsenal. Vetting inhibitor performance across sufficiently diverse cell lines expressing SARS-CoV-2 relevant features will anticipate clinical success.
Without rock-solid biophysical predictors of binding affinity and kinetics, the road from molecular screening and simulation to cell-based assays and in vivo testing is virtually unnavigable. Fully characterizing your COVID-19 drug candidate with a proven SPR methodology is the fundament of the successful development of efficacious drugs.
